EGFR and lung carcinoma: Nevertheless, 10%–20% of lung cancer patients with wild‐type EGFR gained a therapeutic advantage from EGFR TKIs treatment,18, 22, 23 which implied that there are underlying molecular mechanisms that determine the efficacy of EGFR TKIs and are independent of EGFR somatic mutations.